Elmind Capital LP Invests $11.16 Million in Nurix Therapeutics, Inc. $NRIX

Elmind Capital LP acquired a new stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 460,000 shares of the company's stock, valued at approximately $11,159,600. Nurix Therapeutics makes up approximately 0.0% of Elmind Capital LP's investment portfolio, making the stock its 14th biggest holding. Elmind Capital LP owned 0.44% of Nurix Therapeutics as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Larson Financial Group LLC boosted its stake in Nurix Therapeutics by 339.0% during the fourth quarter. Larson Financial Group LLC now owns 1,541 shares of the company's stock valued at $29,000 after buying an additional 1,190 shares in the last quarter. Intesa Sanpaolo Wealth Management bought a new stake in shares of Nurix Therapeutics in the fourth quarter worth $31,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Nurix Therapeutics in the fourth quarter valued at approximately $33,000. KBC Group NV acquired a new stake in Nurix Therapeutics in the first quarter valued at approximately $34,000. Finally, Wexford Capital LP acquired a new position in Nurix Therapeutics in the third quarter valued at approximately $41,000.

Nurix Therapeutics Stock Down 2.5%

NRIX stock traded down $0.66 during trading on Friday, reaching $26.22. The stock had a trading volume of 536,602 shares, compared to its average volume of 1,456,106. Nurix Therapeutics, Inc. has a one year low of $8.19 and a one year high of $28.23. The company has a market capitalization of $2.72 billion, a price-to-earnings ratio of -7.60 and a beta of 1.79. The company's 50 day moving average is $24.20 and its two-hundred day moving average is $18.94.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its earnings results on Thursday, July 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.08). Nurix Therapeutics had a negative return on equity of 76.09% and a negative net margin of 928.44%.The firm had revenue of $9.04 million during the quarter, compared to the consensus estimate of $15.29 million. As a group, research analysts predict that Nurix Therapeutics, Inc. will post -2.73 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Nurix Therapeutics in a research note on Friday, July 17th. Royal Bank Of Canada lifted their target price on shares of Nurix Therapeutics from $33.00 to $36.00 and gave the company an "outperform" rating in a report on Monday, August 10th. Wells Fargo & Company cut shares of Nurix Therapeutics from an "overweight" rating to a "hold" rating and dropped their price objective for the company from $28.00 to $25.00 in a report on Monday, June 8th. UBS Group boosted their price target on Nurix Therapeutics from $23.00 to $31.00 and gave the stock a "buy" rating in a research note on Wednesday, July 22nd. Finally, HC Wainwright lifted their price objective on Nurix Therapeutics from $32.00 to $34.00 and gave the stock a "buy" rating in a report on Friday, July 10th. Thirteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Nurix Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $34.21.

Insider Transactions at Nurix Therapeutics

In other Nurix Therapeutics news, insider Gwenn Hansen sold 5,394 shares of Nurix Therapeutics stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $20.00, for a total value of $107,880.00. Following the transaction, the insider directly owned 115,005 shares in the company, valued at approximately $2,300,100. The trade was a 4.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Houte Hans Van sold 4,761 shares of the firm's stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $24.36, for a total value of $115,977.96. Following the completion of the transaction, the chief financial officer owned 40,166 shares in the company, valued at approximately $978,443.76. This trade represents a 10.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 25,314 shares of company stock valued at $589,361. Corporate insiders own 6.70% of the company's stock.

About Nurix Therapeutics

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company's pipeline includes multiple programs in various stages of development.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source